Cargando…

FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate

BACKGROUND: FDG PET-CT is generally not suitable for diagnosing prostate cancer because of low glycolysis of the tumor cells. Neuroendocrine differentiation of the prostate cancer is often associated with early visceral metastasis and dismal prognosis, which is resulted from changed metabolic and re...

Descripción completa

Detalles Bibliográficos
Autor principal: Liu, Yiyan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440384/
https://www.ncbi.nlm.nih.gov/pubmed/18565231
http://dx.doi.org/10.1186/1477-7819-6-64
_version_ 1782156542435393536
author Liu, Yiyan
author_facet Liu, Yiyan
author_sort Liu, Yiyan
collection PubMed
description BACKGROUND: FDG PET-CT is generally not suitable for diagnosing prostate cancer because of low glycolysis of the tumor cells. Neuroendocrine differentiation of the prostate cancer is often associated with early visceral metastasis and dismal prognosis, which is resulted from changed metabolic and regulatory pathways. CASE PRESENTATION: A case is reported in this paper that FDG PET-CT demonstrates intense uptake of neuroendocrine tumor of the prostate and multiple metastases. CONCLUSION: There is high glycolysis and strong FDG-avidity of neuroendocrine tumor of the prostate, which is similar to that of high grade of neuroendocrine tumor in other tissue and organs. In some selected cases of prostate neuroendocrine cancer, whole body FDG PET-CT may be helpful for detection of metastatic disease.
format Text
id pubmed-2440384
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24403842008-06-27 FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate Liu, Yiyan World J Surg Oncol Case Report BACKGROUND: FDG PET-CT is generally not suitable for diagnosing prostate cancer because of low glycolysis of the tumor cells. Neuroendocrine differentiation of the prostate cancer is often associated with early visceral metastasis and dismal prognosis, which is resulted from changed metabolic and regulatory pathways. CASE PRESENTATION: A case is reported in this paper that FDG PET-CT demonstrates intense uptake of neuroendocrine tumor of the prostate and multiple metastases. CONCLUSION: There is high glycolysis and strong FDG-avidity of neuroendocrine tumor of the prostate, which is similar to that of high grade of neuroendocrine tumor in other tissue and organs. In some selected cases of prostate neuroendocrine cancer, whole body FDG PET-CT may be helpful for detection of metastatic disease. BioMed Central 2008-06-19 /pmc/articles/PMC2440384/ /pubmed/18565231 http://dx.doi.org/10.1186/1477-7819-6-64 Text en Copyright © 2008 Liu; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Liu, Yiyan
FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate
title FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate
title_full FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate
title_fullStr FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate
title_full_unstemmed FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate
title_short FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate
title_sort fdg pet-ct demonstration of metastatic neuroendocrine tumor of prostate
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440384/
https://www.ncbi.nlm.nih.gov/pubmed/18565231
http://dx.doi.org/10.1186/1477-7819-6-64
work_keys_str_mv AT liuyiyan fdgpetctdemonstrationofmetastaticneuroendocrinetumorofprostate